Psilocybine services in Oregon: a call for awareness among clinical toxicologists.
Daniel L. Sudakin
Clinical Toxicology March 1, 2023 DOI: 10.1080/15563650.2023.2182664 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | Psilocybine |
| Topics | Psilocybin |
| Keywords | Psilocybine Adverse event Toxicology Psychedelics hallucinogens Entheogens Public health healthcare Community health Population health Risk management Patient monitoring |
| Citations | 6 |
| Key points | Argues that Oregon's psilocybine regulatory framework raises issues regarding non-clinical facilitator scope, adverse event management, and dosing uncertainties for individuals with medical conditions. |
Abstract
In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators. This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions. This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.
Citations in the library
Cited by 2
- Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022. Annals of emergency medicine December 1, 2024
- "Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms. Toxicon June 7, 2025
Cites 9
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Serotonin toxicity of serotonergic psychedelics Psychopharmacology July 12, 2021
- Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants Clinical Pharmacology & Therapeutics December 12, 2022
- Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy American Journal of Psychotherapy July 23, 2021
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review Psychopharmacology March 7, 2022
and 4 more in the library